Colchicine in Coronary Artery Bypass Graft (CABG)

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: G.Gennimatas General Hospital
• Collaborator: Evangelismos Hospital
• Treatments: Colchicine

Criteria

Inclusion Criteria:

• The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.

Exclusion Criteria:

Excluded are patients:

• with age > 80 years old

• scheduled for concomitant valve surgery

• scheduled for coronary surgery without cardiopulmonary bypass

• with peripheral vascular disease affecting the upper limbs

• with acute coronary syndrome within the previous 4 weeks

• on inotropic or mechanical circulatory support before induction of anaesthesia

• with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)

• with active inflammatory diseases, infectious diseases or known malignancy

• under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents

• with known hypersensitivity-allergy to colchicine

• under chronic treatment with colchicine

• with severe renal failure (eGFR < 35 ml/min/1.73 m2)

• with hepatic failure (Child - Pugh class B or C)